Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
epcoritamab | Biologic Licensing Application | 2023-05-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
large b-cell lymphoma diffuse | — | D016403 | C83.3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Follicular lymphoma | D008224 | — | C82 | 4 | 7 | 1 | — | 1 | 9 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 5 | 2 | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 2 | — | — | — | 4 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 2 | — | — | — | 2 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 1 | 1 | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma | D016393 | — | — | — | — | — | — | 1 | 1 |
Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
Drug common name | Epcoritamab |
INN | epcoritamab |
Description | Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 2134641-34-0 |
RxCUI | — |
ChEMBL ID | CHEMBL4650393 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16672 |
UNII ID | D6OMY2L0WA (ChemIDplus, GSRS) |